Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

DOI record: { "DOI": "10.1007/s00705-021-04956-9", "ISSN": [ "0304-8608", "1432-8798" ], "URL": "http://dx.doi.org/10.1007/s00705-021-04956-9", "alternative-id": [ "4956" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "14 October 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "25 November 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "25 January 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Date", "name": "change_date", "order": 4, "value": "3 August 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Type", "name": "change_type", "order": 5, "value": "Clarification" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Details", "name": "change_details", "order": 6, "value": "Editor's Note:The Editor-in-Chief is currently investigating this article as concerns have been raised about the reporting of this clinical trial. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full." }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Date", "name": "change_date", "order": 7, "value": "22 November 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Type", "name": "change_type", "order": 8, "value": "Correction" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Details", "name": "change_details", "order": 9, "value": "This article has been retracted. Please see the Retraction Notice for more detail:" }, { "URL": "https://doi.org/10.1007/s00705-021-05307-4", "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Change Details", "name": "change_details", "order": 10, "value": "https://doi.org/10.1007/s00705-021-05307-4" }, { "group": { "label": "Compliance with ethical standards", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "There are no conflicts of interest." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Dabbous", "given": "Hany M.", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0003-4366-2218", "affiliation": [], "authenticated-orcid": false, "family": "Abd-Elsalam", "given": "Sherief", "sequence": "additional" }, { "affiliation": [], "family": "El-Sayed", "given": "Manal H.", "sequence": "additional" }, { "affiliation": [], "family": "Sherief", "given": "Ahmed F.", "sequence": "additional" }, { "affiliation": [], "family": "Ebeid", "given": "Fatma F. S.", "sequence": "additional" }, { "affiliation": [], "family": "El Ghafar", "given": "Mohamed Samir Abd", "sequence": "additional" }, { "affiliation": [], "family": "Soliman", "given": "Shaimaa", "sequence": "additional" }, { "affiliation": [], "family": "Elbahnasawy", "given": "Mohamed", "sequence": "additional" }, { "affiliation": [], "family": "Badawi", "given": "Rehab", "sequence": "additional" }, { "affiliation": [], "family": "Tageldin", "given": "Mohamed Awad", "sequence": "additional" } ], "container-title": "Archives of Virology", "container-title-short": "Arch Virol", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2021, 1, 25 ] ], "date-time": "2021-01-25T10:06:58Z", "timestamp": 1611569218000 }, "deposited": { "date-parts": [ [ 2023, 10, 19 ] ], "date-time": "2023-10-19T01:58:46Z", "timestamp": 1697680726000 }, "indexed": { "date-parts": [ [ 2024, 5, 13 ] ], "date-time": "2024-05-13T16:01:05Z", "timestamp": 1715616065990 }, "is-referenced-by-count": 108, "issue": "3", "issued": { "date-parts": [ [ 2021, 1, 25 ] ] }, "journal-issue": { "issue": "3", "published-print": { "date-parts": [ [ 2021, 3 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 1, 25 ] ], "date-time": "2021-01-25T00:00:00Z", "timestamp": 1611532800000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 1, 25 ] ], "date-time": "2021-01-25T00:00:00Z", "timestamp": 1611532800000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s00705-021-04956-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s00705-021-04956-9/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s00705-021-04956-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "949-954", "prefix": "10.1007", "published": { "date-parts": [ [ 2021, 1, 25 ] ] }, "published-online": { "date-parts": [ [ 2021, 1, 25 ] ] }, "published-print": { "date-parts": [ [ 2021, 3 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1056/NEJMoa2001017", "author": "N Zhu", "doi-asserted-by": "publisher", "first-page": "727", "issue": "8", "journal-title": "N Engl J Med.", "key": "4956_CR1", "unstructured": "Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382(8):727–733", "volume": "382", "year": "2020" }, { "DOI": "10.1111/resp.13196", "author": "Y Yin", "doi-asserted-by": "publisher", "first-page": "130", "issue": "2", "journal-title": "Respirology", "key": "4956_CR2", "unstructured": "Yin Y, Wunderink RG (2018) MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 23(2):130–137", "volume": "23", "year": "2018" }, { "author": "M Cascella", "key": "4956_CR3", "unstructured": "Cascella M, Rajnik M, Cuomo A et al (2012) Features, evaluation and treatment coronavirus (COVID-19). StatPearls Publishing, Treasure Island", "volume-title": "Features, evaluation and treatment coronavirus (COVID-19)", "year": "2012" }, { "DOI": "10.7326/M20-1334", "author": "J Yazdany", "doi-asserted-by": "publisher", "first-page": "754", "journal-title": "Ann Intern Med.", "key": "4956_CR4", "unstructured": "Yazdany J, Kim AHJ (2020) Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 172:754–755", "volume": "172", "year": "2020" }, { "DOI": "10.7326/M20-2496", "author": "AV Hernandez", "doi-asserted-by": "publisher", "first-page": "287", "issue": "4", "journal-title": "Ann Intern Med.", "key": "4956_CR5", "unstructured": "Hernandez AV, Roman YM, Pasupuleti V et al (2020) Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 173(4):287–296", "volume": "173", "year": "2020" }, { "DOI": "10.1002/cpt.1844", "author": "YX Du", "doi-asserted-by": "publisher", "first-page": "242", "issue": "2", "journal-title": "Clin Pharmacol Ther", "key": "4956_CR6", "unstructured": "Du YX, Chen XP (2020) Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther 108(2):242–247", "volume": "108", "year": "2020" }, { "DOI": "10.1136/bmjopen-2020-039730", "author": "M Arab-Zozani", "doi-asserted-by": "publisher", "first-page": "e039730", "issue": "7", "journal-title": "BMJ Open.", "key": "4956_CR7", "unstructured": "Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D (2020) Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. BMJ Open. 10(7):e039730", "volume": "10", "year": "2020" }, { "DOI": "10.1073/pnas.1811345115", "author": "DH Goldhill", "doi-asserted-by": "publisher", "first-page": "11613", "issue": "45", "journal-title": "Proc Natl Acad Sci", "key": "4956_CR8", "unstructured": "Goldhill DH, Te Velthuis AJ, Fletcher RA et al (2018) The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci 115(45):11613–11618", "volume": "115", "year": "2018" }, { "DOI": "10.1177/2472555220942123", "author": "W Zhu", "doi-asserted-by": "publisher", "journal-title": "SLAS DISCOV Adv Sci Drug Discov", "key": "4956_CR9", "unstructured": "Zhu W, Chen CZ, Gorshkov K et al (2020) RNA-dependent RNA polymerase as a target for COVID-19 Drug discovery. SLAS DISCOV Adv Sci Drug Discov. https://doi.org/10.1177/2472555220942123", "year": "2020" }, { "DOI": "10.1080/07391102.2020.1761882", "author": "AA Elfiky", "doi-asserted-by": "publisher", "journal-title": "J Biomol Struct Dyn", "key": "4956_CR10", "unstructured": "Elfiky AA (2020) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1761882", "year": "2020" }, { "DOI": "10.2174/1871526520666200520112848", "author": "AA Mohamed", "doi-asserted-by": "publisher", "journal-title": "Infect Disord Drug Targets", "key": "4956_CR11", "unstructured": "Mohamed AA, Mohamed N, Mohamoud S et al (2020) SARS-CoV-2: the path of prevention and control. Infect Disord Drug Targets. https://doi.org/10.2174/1871526520666200520112848 (Online ahead of print)", "year": "2020" }, { "DOI": "10.1007/s12072-020-10072-8", "author": "SK Sarin", "doi-asserted-by": "publisher", "first-page": "690", "issue": "5", "journal-title": "Hepatol Int", "key": "4956_CR12", "unstructured": "Sarin SK, Choudhury A, Lau GK et al (2020) Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int 14(5):690–700. https://doi.org/10.1007/s12072-020-10072-8", "volume": "14", "year": "2020" }, { "DOI": "10.2174/1871526520666200726224802", "author": "S Abd-Elsalam", "doi-asserted-by": "publisher", "journal-title": "Infect Disord Drug Targets.", "key": "4956_CR13", "unstructured": "Abd-Elsalam S, Elkadeem M, Glal KA (2020) Chloroquine as chemoprophylaxis for COVID-19: Will this work? Infect Disord Drug Targets. https://doi.org/10.2174/1871526520666200726224802 (Online ahead of print)", "year": "2020" }, { "DOI": "10.2174/1871530320999201117142305", "author": "S Abd-Elsalam", "doi-asserted-by": "publisher", "journal-title": "Endocr Metab Immune Disord Drug Targets", "key": "4956_CR14", "unstructured": "Abd-Elsalam S, Esmail ES, Khalaf M et al (2020) Tanta protocol for management of COVID-19. Perspectives from a developing country. Endocr Metab Immune Disord Drug Targets. https://doi.org/10.2174/1871530320999201117142305 (Online ahead of print)", "year": "2020" }, { "DOI": "10.1016/j.ijid.2020.03.071", "author": "M Xie", "doi-asserted-by": "publisher", "journal-title": "Int J Infect Dis", "key": "4956_CR15", "unstructured": "Xie M, Chen Q (2020) Insight into 2019 novel coronavirus—an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2020.03.071 ([Epub ahead of print])", "year": "2020" }, { "DOI": "10.1016/j.jhep.2020.09.024", "author": "T Marjot", "doi-asserted-by": "publisher", "journal-title": "J Hepatol", "key": "4956_CR16", "unstructured": "Marjot T, Moon AM, Cook JA et al (2020) Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. https://doi.org/10.1016/j.jhep.2020.09.024 (Online ahead of print. PMID: 33035628)", "year": "2020" }, { "DOI": "10.1016/j.eng.2020.03.007", "author": "Q Cai", "doi-asserted-by": "publisher", "journal-title": "Engineering (Beijing)", "key": "4956_CR17", "unstructured": "Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). https://doi.org/10.1016/j.eng.2020.03.007 ([Epub ahead of print])", "year": "2020" }, { "DOI": "10.3758/BF03193146", "author": "F Faul", "doi-asserted-by": "publisher", "first-page": "175", "journal-title": "Behav Res Methods", "key": "4956_CR18", "unstructured": "Faul F, Erdfelder E, Lang A-G et al (2007) A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191", "volume": "39", "year": "2007" }, { "key": "4956_CR19", "unstructured": "World Health Organization. Coronavirus disease (COVID-19) situation report—139. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.pdf?sfvrsn=79dc6d08_2. Accessed 8 June 2020." }, { "DOI": "10.1016/j.antiviral.2014.02.014", "author": "L Oestereich", "doi-asserted-by": "publisher", "first-page": "17", "journal-title": "Antiviral Res", "key": "4956_CR20", "unstructured": "Oestereich L, Lüdtke A, Wurr S et al (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17–21", "volume": "105", "year": "2014" }, { "DOI": "10.1016/j.antiviral.2015.08.015", "author": "V Madelain", "doi-asserted-by": "publisher", "first-page": "70", "journal-title": "Antiviral Res", "key": "4956_CR21", "unstructured": "Madelain V, Oestereich L, Graw F et al (2015) Ebola virus dynamics in mice treated with favipiravir. Antiviral Res 123:70–77", "volume": "123", "year": "2015" }, { "key": "4956_CR22", "unstructured": "Noda A, Shirai T, Nakajima H et al (2020) Case report: two cases of COVID-19 pneumonia including use of favipiravir. The Japanese Association for Infectious Diseases. http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200408_2.pdf" }, { "key": "4956_CR23", "unstructured": "Yokoyama K, Oguri T, Kato A et al (2020) Case report a case of COVID-19 pneumonia that did not worsen and was relieved by early administration of favipiravir and ciclesonide. http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200406.pdf." }, { "DOI": "10.4269/ajtmh.20-0290", "author": "PM Abena", "doi-asserted-by": "publisher", "first-page": "1184", "journal-title": "Am J Trop Med Hyg", "key": "4956_CR24", "unstructured": "Abena PM et al (2020) Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg 102:1184–1188", "volume": "102", "year": "2020" }, { "DOI": "10.1128/AAC.49.3.981-986.2005", "author": "Y Furuta", "doi-asserted-by": "publisher", "first-page": "981", "journal-title": "Antimicrob Agents Chemother.", "key": "4956_CR25", "unstructured": "Furuta Y et al (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 49:981–986", "volume": "49", "year": "2005" }, { "DOI": "10.1111/cts.12827", "author": "K Irie", "doi-asserted-by": "crossref", "first-page": "880", "issue": "5", "journal-title": "Clin Transl Sci.", "key": "4956_CR26", "unstructured": "Irie K, Nakagawa A, Fujita H et al (2020) Pharmacokinetics of favipiravir in critically Ill patients with COVID-19. Clin Transl Sci. 13(5):880–885", "volume": "13", "year": "2020" }, { "DOI": "10.1186/s13054-020-03078-z", "author": "K Doi", "doi-asserted-by": "publisher", "first-page": "392", "journal-title": "Crit Care", "key": "4956_CR27", "unstructured": "Doi K, Ikeda M, Hayase N et al (2020) Nafamostat mesylate treatment incombination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care 24:392", "volume": "24", "year": "2020" }, { "author": "H Inoue", "first-page": "101200", "journal-title": "Respir Med Case Rep", "key": "4956_CR28", "unstructured": "Inoue H, Jinno M, Ohta S et al (2020) Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respir Med Case Rep 31:101200", "volume": "31", "year": "2020" } ], "reference-count": 28, "references-count": 28, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s00705-021-04956-9" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "update-to": [ { "DOI": "10.1007/s00705-021-04956-9", "label": "Retraction", "type": "retraction", "updated": { "date-parts": [ [ 2021, 11, 22 ] ], "date-time": "2021-11-22T00:00:00Z", "timestamp": 1637539200000 } } ], "volume": "166" }